

9/7/1 (Item 1 from file: 351)  
DIALOG(R)File 351:Derwent WPI  
(c) 2004 Thomson Derwent. All rts. reserv.

008434112

WPI Acc No: 1990-321112/\*\*199043\*\*

Neutralising monoclonal antibodies against human interferon alpha -  
prepd. by usual cell fusion then characterisation in neutralisation test  
before establishing stable hybridomas

Patent Assignee: AKAD WISSENSCHAFTEN DDR (DEAK )

Inventor: FRITZKE H; MUNSTER H; TONEW M; WISNIEWSKI H G; WOLLWEBER L

Number of Countries: 001 Number of Patents: 001

Patent Family:

| Patent No | Kind | Date | Applicat No | Kind | Date | Week |
|-----------|------|------|-------------|------|------|------|
|-----------|------|------|-------------|------|------|------|

|           |   |          |           |   |          |          |
|-----------|---|----------|-----------|---|----------|----------|
| DD 277087 | A | 19900321 | DD 321978 | A | 19881121 | 199043 B |
|-----------|---|----------|-----------|---|----------|----------|

Priority Applications (No Type Date): DD 321978 A 19881121

Abstract (Basic): DD 277087 A

Prodn. of neutralising monoclonal antibodies (MAb) against human interferon (IFN) alpha comprises (1) immunising BALB/c mice with native IFN alpha; (2) fusing spleen cells with myeloma cells; (3) selecting the resulting hybridomas; (4) determination of antigen determinant specificity by ELISA and solid phase bioassay; (5) biological characterisation of the MAb produced by a neutralisation test; (b) cloning and recloning selected hybridomas by micromanipulation of individual cells in a special appts. to establish stable hybridoma lines; (7) cultivating or transplanting the new hybridomas H/B 71C6 or H/B 71E3 (ZIM 0283 and 0284, respectively), and (8) recovering MAb ZIMET B71C6 or B71E3 from the culture supernatant or ascites fluid.

USE/ADVANTAGE - MAb are useful for (1) neutralising biological activity of IFN-alpha in biological or medical research; (2) for immunochemical diagnostic determinations and (3) for immuno-affinity chromatographic purification of IFN-alpha. (3pp Dwg.No.0/0)

Derwent Class: B04; D16

International Patent Class (Additional): C12N-005/02; C12P-021/00